Equity Research, Broker Reports, and media content on VISTIN PHARMA AS

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about VISTIN PHARMA AS
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on VISTIN PHARMA AS. We currently have 0 research reports from 0 professional analysts.

Open
0.00
Volume
0.0m
Range
0.00/0.00
Market Cap
0m
52 Week
0.00/0.00

Latest News/RNS

(more news)
Date Source Announcement
28Feb17 06:00 GNW Vistin Pharma ASA : Fourth quarter and preliminary 2016 results
31Oct16 06:01 GNW Vistin Pharma ASA third quarter 2016: Investing in future growth
30Aug16 06:31 GNW Vistin Pharma ASA : Vistin Pharma to double its metformin production capacity by 2019 with MNOK 120 investment
30Aug16 06:30 GNW Vistin Pharma ASA : Solid second quarter driven by all-time high metformin revenue
28Apr16 06:00 GNW Vistin Pharma ASA : Strong first quarter 2016 and bright outlook
23Feb16 06:00 GNW Vistin Pharma ASA : Solid fourth quarter results and positive market outlook
29Oct15 06:01 GNW Vistin Pharma ASA : Third quarter 2015 results
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    VISTIN PHARMA AS

  • Providers covering

    VISTIN PHARMA AS

  • 16 Jun 17

N+1 Singer - Morning Song 16-06-2017

Ergomed (ERGO LN) Dr Dan Weng appointed CEO | Severfield (SFR LN) Continuing to deliver on the strategy

Companies: Ergomed Severfield

  • 22 Jun 17

N+1 Singer - Uncovered Gems - Speed Dating Lunch - Another five sparkling gems

Last Friday we reprised our successful speed dating format with excellent presentations from the CEOs of Access Intelligence, Corero Network Security, LiDCO Group, OrganOx and Yu Group. Each company gave a ten minute overview of its business and the investment case and we had quick-fire Q&A from a group of fund managers. Below we summarise our thoughts on each company, with more details inside, plus we include the slides presented by each management team. We believe all five companies have excellent potential and are happy to arrange further contact. We also look forward to setting up our next speed dating event.

Companies: ACC CNS LID YU/

  • 19 Jun 17

Morning Note

Europa Oil & Gas* (EOG): Irish licence update (CORP) | Victoria* (VCP): Share price fall is entry opportunity (CORP) | CareTech (CTH): Interims, acquisitions and upgrades (BUY)

Companies: EOG CTH VCP

  • 22 Jun 17

N+1 Singer - Morning Song 22-06-2017

Carador Income Fund (CIFU LN) Level of refinancing and reset activity remains high | Imagination Technologies Group (IMG LN) No progress with Apple; Whole group for sale | Uncovered Gems - Speed Dating Lunch Another five sparkling gems

Companies: IMG CIFU ACC CNS LID YU/

  • 20 Jun 17

Focus on integration and growth

Abzena reported solid FY17 results with underlying revenue growth of 41% (to £18.7m). In FY17, Abzena continued to focus on the integration of its service offering across its three sites (US and UK), which has been expanded by its recent placing of £25m gross (issuing 75.8m new shares at 33p). We expect this to enable strong growth and take Abzena to profitability in FY20, which will be a significant milestone for the company. We maintain our valuation at £132m, 62p per share, but note potential upside as it demonstrates growth and as Abzena inside products progress.

Companies: Abzena
  • 19 Jun 17

Small Cap Breakfast

FFI Holdings— specialist in the provision of completion contracts to the entertainment industry for films, television, miniseries and streaming product. Offer TBA. Expected 30 June. QUIZ— omni-channel fast fashion womenswear Company intention to float. Due July 2017. Offer TBA Ethernity Networks—Schedule 1 from Israeli based specialist in data processing technology used in high end carrier ethernet applications across the telecom, mobile, security and data centre markets . Expected late June. Offer TBA. Jangada Mines—Schedule 1 advanced stage PGM exploration project containing what the Directors understand to be the largest PGM resource, as well as being the only pre-development PGM project, in South America. Offer TBA. Expected late June. Phoenix Global Mining— US Brown field copper play. Expected late June. Offer TBA Touchstone Exploration— Oil exploration and production company active in the Republic of Trinidad and Tobago. Interests of approximately 90,000 gross acres. Production c. 1,300 boepd. Raising £1.45m. Expected mkt cap £7.5m. Due 26 June. I3 Energy –Schedule 1. Independent oil and gas company with assets and operations in the UK. Offer TBC, 7 June admission. Verditek— Schedule 1 update. On Admission, the Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Issue price 10p. Admission late June Tiso Blackstar Group—Schedule 1 update. Media, entertainment and marketing solutions group/ £160m mkt cap. Admission only. Expected late June. sidential Secure Income - social housing REIT raising up to £300m Admission due c.12 July. ScotGems—Admission due 26 June. Seeking £50-£100m. To investing in a diversified portfolio of Small Cap Companies listed on global stock markets DP Eurasia—Intention to float from the exclusive master franchisee of the Domino's Pizza brand in Turkey, Russia, Azerbaijan and Georgia . £20m primary raise plus a partial vendor sale. AIB—Intention to float from AIB, Ireland's leading retail and commercial bank . The Minister for Finance intends to sell approximately 25% of the Ordinary Shares of AIB. Valuation range €10.6-€13.3bn. Admission end June. Curzon Energy—Report on Proactive Investors of intended LSE float this year with acquisition of coal bed methane assets in Oregon. Looking to raise £3m plus. NLB Group—financial and banking institution based in Slovenia, with a network of 356 branches. Seeking Ljubliana Stock Exchange listing with GDRs on the LSE. Expected mid June. Kuwait Energy— $150m raise plus vendor offer. Admission due June. 2p reserves 810.0 mmboe

Companies: IDP SKIN IVO MSYS CTH SAR ARL PTSG MWE MAFL

  • 21 Jun 17

N+1 Singer - Morning Song 21-06-2017

Ergomed (ERGO LN) Top line PeproStat™ Phase IIb data now expected in Q4 2017 | Touchstone Innovations (IVO LN) IP Group confirms Takeover Offer | Walker Greenbank (WGB LN) Strong o/seas & manufacturing demand counter soft patch in UK in May

Companies: WGB IVO ERGO

  • 19 Jun 17

The acquisitions begin…

CareTech has announced in line interim results and the acquisition of an Adult Learning Disabilities business which adds circa £2.4m to EBITDA. Investment in management and infrastructure ahead of further scaling of the business tempers our upgrades but CareTech remains well positioned to take advantage of the consolidation in this expanding sector. We increase our target price to 470p (previously 458p) and reiterate of BUY recommendation.

Companies: CareTech
  • 11 Apr 17

£70m contracted revenues still to come

2016 perfectly highlighted the strengths of the Ergomed business: the visibility of its Contracted Revenues and the potential upside from co-development deals. Contracted revenues now stand at an impressive £70m, up from £42m and the outlook remains auspicious. FY2016 came in ahead of revised forecasts and there are upgrades to FY2017 onwards. Meanwhile, Haemostatix is moving into the next phase of clinical trials, and the co-development programmes continue to progress. Our valuation range/share has increased to 232p - 437p.

Companies: Ergomed
  • 19 Jun 17

Satisfactory beginning; receding headwinds to improve growth momentum

After a disappointing end to FY 16, Smith & Nephew (S&N) exhibited improved sequential sales evolution in Q1 17 (trading update, only sales disclosed) – underlying sales grew 3% (the highest since Q1 16) to $1.1bn, in line with consensus expectations. However, a negative disposal impact of 2% and a currency headwind of 1% neutralised the underlying expansion, resulting in the reported growth being flat. On a geographical basis, the underlying recovery was primarily driven by the strong uptick in emerging markets growth (12% vs. 3% in Q4 16 and -6% in Q1 16) on the back of a sturdy Chinese performance (+14%) and annualisation of the Gulf headwinds. Meanwhile, established markets (including both the US and other established markets) remained weak, recording an underlying growth of 1%. Notably, franchise-wise (underlying basis), advanced wound care turned positive (1%; after remaining flat or negative throughout FY 16) while knee implants (5%. vs. +9% in Q1 16), sports medicine joint repair (7% vs. 11% in Q1 16), trauma & extremities (5% vs. -7% in Q1 16) and advanced wound devices (+16% vs. Q1 16: +11%) all contributed healthily. Conversely, hip implants remained flat (vs. +4% in Q1 16) while weak arthroscopic-enabling technologies (-1% vs. Q1 16: +4%) and advanced wound bioactives (-8% vs. Q1 16: -4%) adversely impacted the performance. Based on current exchange rates, management now expects a currency headwind of 0.6% (previously 1%). Factoring in the reduced currency headwind, management has slightly increased its reported revenue growth estimate to 1.6-2.6% from the previous 1.2-2.2% while maintaining its underlying revenue guidance of 3-4%.

Companies: Smith & Nephew
  • 19 Jun 17

N+1 Singer - Morning Song 19-06-2017

Microsaic Systems (MSYS LN) Challenges persist, but encouraging progress with biopharma strategy | ReNeuron Group (RENE LN) FDA approval of cryopreserved formulation of hRPC candidate | Sinclair Pharma (SPH LN) Acquisition of Refine™ broadens the aesthetic portfolio

Companies: SPH RENE MSYS

  • 15 Jun 17

Morning Note

OptiBiotix* (OPTI): Supply agreement with HLH (CORP) | Seeing Machines* (SEE): Guardian arrives in the UK (CORP)

Companies: Optibiotix Health Seeing Machines

  • 22 Jun 17

Small Cap Breakfast

GYG—Intention to float by the superyacht painting, supply and maintenance company. Due 5 July. Raising £6.9m new plus vendor sale of £21.5m at 100p. Mkt Cap c. £47m. Revenue of €54.6m in FY16 and adjusted EBITDA of €6.7m. Greencoat Renewables - Schedule 1. Targeting a portfolio of operating renewable electricity generation assets, initially investing in wind generation assets in Ireland. Offer TBC. Due Mid July. FFI Holdings— Specialist in the provision of completion contracts to the entertainment industry for films, television, mini-series and streaming product. Offer TBA. Expected 30 June. QUIZ— Omni-channel fast fashion womenswear Company intention to float. Due July 2017. Offer TBA Ethernity Networks—Schedule 1 from Israeli based specialist in data processing technology used in high end carrier ethernet applications across the telecom, mobile, security and data centre markets. Expected late June. Offer TBA. Jangada Mines—Sch 1 advanced stage PGM exploration project containing what the Directors understand to be the largest PGM resource, and only pre-development PGM project, in South America. Offer TBA. Expected late June. Phoenix Global Mining— US Brown field copper play. Expected late June. Offer TBA Touchstone Exploration— Oil E&P company active in the Republic of Trinidad and Tobago. Interests of approximately 90k gross acres. Production c. 1.3k boepd. Raising £1.5m. Expected mkt cap £7.5m - 26 June. I3 Energy –Schedule 1. Independent oil and gas company with assets and operations in the UK. Offer TBC, 7 June admission. Verditek— Schedule 1 update. On Admission, the Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Issue price 10p. Admission late June Tiso Blackstar Group—Schedule 1 update. Media, entertainment and marketing solutions group/ £160m mkt cap. Admission only. Postponed. Rockpool Acquisitions—Northern Ireland based Company seeking strong NI acquisition with an international outlook. Raising £1.5m at 10p. Due 5 July. Residential Secure Income - social housing REIT raising up to £300m Admission due c.12 July. ScotGems—Admission due 26 June. Seeking £50-£100m. To investing in a diversified portfolio of Small Cap Companies listed on global stock markets DP Eurasia—Intention to float from the exclusive master franchisee of the Domino's Pizza brand in Turkey, Russia, Azerbaijan and Georgia . £20m primary raise plus a partial vendor sale. AIB—Intention to float from AIB, Ireland's leading retail and commercial bank. The Minister for Finance intends to sell approximately 25% of the Ordinary Shares of AIB. Valuation range €10.6-€13.3bn. Admission end June. Curzon Energy—Report on Proactive Investors of intended LSE float this year with acquisition of coal bed methane assets in Oregon. Looking to raise £3m plus. NLB Group—financial and banking institution based in Slovenia, with a network of 356 branches. Seeking Ljubliana Stock Exchange listing with GDRs on the LSE. Expected mid June. Kuwait Energy— $150m raise plus vendor offer. Admission due June. 2p reserves 810.0 mmboe Supermarket Income REIT– Up to £200m raise to acquire a diversified portfolio of supermarket real estate assets in the UK, providing long-term RPI-linked income. Due 21 July.

Companies: VLS GSH EGI MSG FDEV UNG TND LTHM REDX CREO

  • 19 Jun 17

N+1 Singer - Sinclair Pharma - Acquisition of Refine™ broadens the aesthetic portfolio

The Refine™ Support System appears to be a good fit with Sinclair’s Silhouette® range of suture-based aesthetic products. In the US, the product will be marketed by ThermiGen, primarily targeting the aesthetic breast surgery market (a 600,000-procedure market in the US alone). Other markets in Europe, LatAm and Asia will be added in due course following regulatory approvals. We reiterate our Buy with a target price of 37p.

Companies: Sinclair Pharma
  • 22 Jun 17

Panmure Morning Note 22-06-2017

Chi-Med has today announced the initiation of a Phase I/II clinical trial of its novel FGFR (fibroblast growth factor receptor) inhibitor HMPL-453 in China. This follows and complements the first in-human Phase I clinical trial of HMPL-453 in Australia that was initiated earlier this year. We consider the momentum behind Chi-Med’s clinical pipeline is strong and growing, both in terms of earlier clinical progress (such as today’s update) and also, of course, the later-stage pipeline as demonstrated by the recent CFDA regulatory submission of the fruquintinib NDA (advanced colorectal cancer). It’s the combined breadth and depth of the portfolio – and the corresponding potential for significant news flow catalysts for the stock – which we think allows Chi-Med to stand out from its peers. We remain Buyers.

Companies: Hutchison China Meditech